Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.

Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.
Breast Cancer
DRUG: Trastuzumab|DRUG: Vinorelbine
Objective Response Rate, CT scan and MUGA scan, Every 9 weeks. Up to 2 years
Progression free survival, CT scan, Every 9 weeks from date of first treatment until progression or death. Up to 2 years|Overall Survival, From date of inclusion until date of death. Up to 2 years.
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.

Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.